Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06926673 · ClinicalTrials.gov registry record · Phase 2
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT06926673 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 62 participants.
The verdict
NCT06926673, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.
Interventions
- DRUG Dostarlimab
- DRUG Nelistotug
- DRUG Belrestotug.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2021-12-23 |
| Est. Completion | 2024-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06926673
The ClinicalTrials.gov registry entry for NCT06926673 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dostarlimab is the first listed.
NCT06926673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06926673 about?
NCT06926673 is a clinical study titled "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3". This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC...
What is the current status of trial NCT06926673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2021-12-23. Estimated completion is 2024-05-02.
What interventions are being tested in trial NCT06926673?
The interventions under investigation include: Dostarlimab (DRUG), Nelistotug (DRUG), Belrestotug. (DRUG).
Who is sponsoring clinical trial NCT06926673?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.